AbbVie Inc.
ABBVUnited States
81 filed reports · 492 financial concepts · 42 earnings calls
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
81 reports · Jun 2016 to Sep 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 135 guidance figures, 32 earnings-release figures, 64 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 39 | 191 | Mar 2017 to Sep 2026 |
| Quarterly · 10-QSEC EDGAR | 32 | 5,548 | Jun 2016 to Sep 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,865 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 10-Q | 2026-09-30 | 2026-11-03 | 335 | Open |
| FY2026 Q3 | 8-K | 2026-09-30 | 2026-10-30 | 34 | Open |
| FY2026 Q2 | 10-Q | 2026-06-30 | 2026-08-03 | 226 | Open |
| FY2026 Q2 | 8-K | 2026-06-30 | 2026-07-31 | 2 | Open |
| FY2026 Q1 | 10-Q | 2026-03-31 | 2026-05-08 | 234 | Open |
| FY2026 Q1 | 8-K | 2026-03-31 | 2026-04-29 | 2 | Open |
| FY2025 | 10-K | 2025-12-31 | 2026-02-20 | 1,100 | Open |
| FY2025 Q4 | 8-K | 2025-12-31 | 2026-02-04 | 2 | Open |
| FY2025 Q3 | 10-Q | 2025-09-30 | 2025-11-04 | 175 | Open |
| FY2025 Q3 | 8-K | 2025-09-30 | 2025-10-31 | 2 | Open |
| FY2025 Q2 | 10-Q | 2025-06-30 | 2025-08-04 | 171 | Open |
| FY2025 Q2 | 8-K | 2025-06-30 | 2025-07-31 | 2 | Open |
Financial data
492 concepts · 11,604 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial463 concepts · 10,601 facts · Sep 2014 to Sep 2026
- Allocated share based compensation expense59 · Dec 2014 to Sep 2026
- Amortization of intangible assets59 · Dec 2014 to Sep 2026
- Cash and cash equivalents at carrying value59 · Dec 2014 to Sep 2026
- Comprehensive income net of tax59 · Dec 2014 to Sep 2026
- Costs and expenses59 · Dec 2014 to Sep 2026
- Depreciation59 · Dec 2014 to Sep 2026
- Earnings per share basic59 · Dec 2014 to Sep 2026
- Earnings per share diluted59 · Dec 2014 to Sep 2026
- Income tax expense benefit59 · Dec 2014 to Sep 2026
- Interest expense (US GAAP)59 · Dec 2014 to Sep 2026
- Interest income expense nonoperating net59 · Dec 2014 to Sep 2026
- Net income loss59 · Dec 2014 to Sep 2026
- Net income loss available to common stockholders basic59 · Dec 2014 to Sep 2026
- Operating income loss59 · Dec 2014 to Sep 2026
- Other nonoperating income expense59 · Dec 2014 to Sep 2026
- Participating securities distributed and undistributed earnings loss diluted59 · Dec 2014 to Sep 2026
- Research and development asset acquired other than through business combination written off59 · Dec 2014 to Sep 2026
- Research and development expense excluding acquired in process cost59 · Dec 2014 to Sep 2026
- Revenue59 · Dec 2014 to Sep 2026
- Selling general and administrative expense59 · Dec 2014 to Sep 2026
- Increase decrease in accounts payable and accrued liabilities57 · Dec 2014 to Sep 2026
- Increase decrease in accounts receivable57 · Dec 2014 to Sep 2026
- Increase decrease in inventories57 · Dec 2014 to Sep 2026
- Increase decrease in prepaid deferred expense and other assets57 · Dec 2014 to Sep 2026
Product6 concepts · 648 facts · Dec 2014 to Sep 2026
- Revenue328 · Dec 2014 to Sep 2026
- Revenue (excluding assessed tax)306 · Mar 2018 to Mar 2026
- Impairment of intangible assets finitelived8 · Sep 2022 to Dec 2025
- Fair value measurement with unobservable inputs reconciliation recurring basis liability gain loss included in earnings4 · Jun 2019 to Dec 2021
- Impairment of intangible assets excluding goodwill1 · Mar 2023
- Impairment of intangible assets indefinitelived excluding goodwill1 · Dec 2024
Geography1 concept · 164 facts · Dec 2014 to Dec 2025
- Revenue164 · Dec 2014 to Dec 2025
Guidance8 concepts · 159 facts · Apr 2017 to Oct 2026
- EPS (Diluted) Guidance77 · Apr 2017 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))48 · Apr 2017 to Oct 2026
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))16 · Oct 2017 to May 2020
- Effective Tax Rate Guidance (Adjusted (non-GAAP))6 · Jan 2018 to Jul 2018
- EPS (Diluted) Growth Guidance6 · Jul 2019 to May 2020
- Revenue Growth Guidance2 · Jan 2018
- Revenue Growth Guidance (Constant currency)2 · Feb 2020
- Revenue Guidance2 · Jan 2018
KPI14 concepts · 32 facts · Sep 2025 to Sep 2026
- Acquired IPR&D and milestones4 · Sep 2025 to Sep 2026
- Net earnings attributable to AbbVie Inc.4 · Sep 2025 to Sep 2026
- Cost of products sold2 · Sep 2025 to Sep 2026
- Earnings before income tax expense2 · Sep 2025 to Sep 2026
- Income tax expense2 · Sep 2025 to Sep 2026
- Interest expense, net2 · Sep 2025 to Sep 2026
- Net earnings2 · Sep 2025 to Sep 2026
- Net revenues2 · Sep 2025 to Sep 2026
- Operating earnings2 · Sep 2025 to Sep 2026
- Other expense, net2 · Sep 2025 to Sep 2026
- Other operating income2 · Sep 2025 to Sep 2026
- Research and development2 · Sep 2025 to Sep 2026
- Selling, general and administrative2 · Sep 2025 to Sep 2026
- Total operating costs and expenses2 · Sep 2025 to Sep 2026
Segments
812 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or serviceus-gaap:ProductOrServiceAxis23 members · 588 facts
- Humira74 · Mar 2018 to Mar 2026
- Duodopa66 · Mar 2018 to Sep 2025
- Imbruvica49 · Mar 2018 to Mar 2026
- Lupron33 · Mar 2018 to Sep 2021
- Duodopa26 · Dec 2014 to Jun 2018
- HUMIRA26 · Dec 2014 to Jun 2018
- Kaletra26 · Dec 2014 to Jun 2018
- Lupron26 · Dec 2014 to Jun 2018
- Sevoflurane26 · Dec 2014 to Jun 2018
- Creon24 · Mar 2018 to Mar 2026
- Imbruvica22 · Dec 2014 to Jun 2018
- Andro Gel20 · Dec 2014 to Jun 2018
- Creon20 · Dec 2014 to Jun 2018
- Synagis20 · Dec 2014 to Jun 2018
- Synthroid20 · Dec 2014 to Jun 2018
- HCV19 · Dec 2015 to Jun 2018
- Kaletra18 · Mar 2018 to Mar 2020
- Other Products18 · Dec 2014 to Jun 2018
- Sevoflurane16 · Mar 2018 to Mar 2020
- Viekira13 · Dec 2014 to Jun 2017
- Synthroid12 · Mar 2018 to Sep 2021
- Andro gel7 · Mar 2018 to Mar 2020
- Synagis7 · Mar 2018 to Mar 2020
Statement geographicalsrt:StatementGeographicalAxis13 members · 120 facts
- BR10 · Dec 2016 to Dec 2025
- CA10 · Dec 2016 to Dec 2025
- DE10 · Dec 2016 to Dec 2025
- ES10 · Dec 2016 to Dec 2025
- FR10 · Dec 2016 to Dec 2025
- GB10 · Dec 2016 to Dec 2025
- IT10 · Dec 2016 to Dec 2025
- JP10 · Dec 2016 to Dec 2025
- Other Countries10 · Dec 2016 to Dec 2025
- US10 · Dec 2016 to Dec 2025
- AU8 · Dec 2018 to Dec 2025
- CN8 · Dec 2018 to Dec 2025
- NL4 · Dec 2016 to Dec 2019
Product or servicesrt:ProductOrServiceAxis8 members · 60 facts
- Other Products46 · Dec 2016 to Sep 2026
- SKYRIZI4 · Jun 2019 to Dec 2021
- Resonic And Durysta3 · Sep 2025 to Dec 2025
- Imbruvica2 · Sep 2023 to Sep 2024
- Liletta And Coolsculpting2 · Dec 2023
- AGN1516071 · Mar 2023
- Emraclidine1 · Dec 2024
- Vuity1 · Sep 2022
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 44 facts
- BR4 · Dec 2014 to Dec 2017
- CA4 · Dec 2014 to Dec 2017
- DE4 · Dec 2014 to Dec 2017
- ES4 · Dec 2014 to Dec 2017
- FR4 · Dec 2014 to Dec 2017
- GB4 · Dec 2014 to Dec 2017
- IT4 · Dec 2014 to Dec 2017
- JP4 · Dec 2014 to Dec 2017
- NL4 · Dec 2014 to Dec 2017
- Other Countries4 · Dec 2014 to Dec 2017
- US4 · Dec 2014 to Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary133 claims from 10 reports · Sep 2024 to Sep 2026
- Management discussion (MD&A) commentary260 claims from 9 reports · Sep 2024 to Sep 2026
- Risk-factor changes43 claims from 9 reports · Dec 2017 to Dec 2025
- Risk factors295 risks from 10 annual reports · 2016 to 2025
Earnings calls
42 calls · Jul 2016 to Oct 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q32026-10-30
- FY2026 Q22026-07-31
- FY2026 Q12026-04-29
- FY2025 Q42026-02-04
- FY2025 Q32025-10-31
- FY2025 Q22025-07-31
- FY2025 Q12025-04-25
- FY2024 Q42025-01-31
- FY2024 Q32024-10-30
- FY2024 Q22024-07-25
- FY2024 Q12024-04-26
- FY2023 Q42024-02-02
- FY2023 Q32023-10-27
- FY2023 Q22023-07-27
- FY2023 Q12023-04-27
- FY2022 Q42023-02-09
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of AbbVie Inc. (ABBV) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.